User profiles for Sophie Poty

Sophie Poty

Institut de Chimie Moléculaire de l'Université de Bourgogne
Verified email at u-bourgogne.fr
Cited by 726

α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 1

S Poty, LC Francesconi, MR McDevitt… - Journal of Nuclear …, 2018 - Soc Nuclear Med
With a short particle range and high linear energy transfer, α-emitting radionuclides demonstrate
high cell-killing efficiencies. Even with the existence of numerous radionuclides that …

α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 2

S Poty, LC Francesconi, MR McDevitt… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The use of radioactive sources to deliver cytotoxic ionizing radiation to disease sites dates
back to the early 20th century, with the discovery of radium and its physiologic effects. α-…

From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience

…, S Paillas, R Ladjohounlou, A Pichard, S Poty… - Nuclear medicine and …, 2022 - Elsevier
Targeted radionuclide therapy (TRT) is used to treat disseminated or metastatic tumours in
which conventional external beam radiotherapy (EBRT) would have unacceptable side effects…

Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma

S Poty, LM Carter, K Mandleywala, R Membreno… - Clinical Cancer …, 2019 - AACR
Purpose: Interest in targeted alpha-therapy has surged due to α-particles' high cytotoxicity.
However, the widespread clinical use of this approach could be limited by on-/off-target …

Innovative magnetic nanoparticles for PET/MRI bimodal imaging

…, P Walker, I Severin, A Oudot, C Goze, S Poty… - ACS …, 2019 - ACS Publications
Superparamagnetic iron oxide nanoparticles were developed as positron emission
tomography (PET) and magnetic resonance imaging (MRI) bimodal imaging agents. These …

A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals

…, HA Park, N Pillarsetty, Y Roux, J Wu, S Poty… - Nuclear medicine and …, 2019 - Elsevier
Introduction Determination of the target-binding fraction (TBF) of radiopharmaceuticals using
cell-based assays is prone to inconsistencies arising from several intrinsic and extrinsic …

Therapeutic antibodies–natural and pathological barriers and strategies to overcome them

…, N Heuzé-Vourc'h, D Lanznaster, S Poty… - Pharmacology & …, 2022 - Elsevier
Antibody-based therapeutics have become a major class of therapeutics with over 120
recombinant antibodies approved or under review in the EU or US. This therapeutic class has …

[HTML][HTML] Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide

MB Idrissou, A Pichard, B Tee, T Kibedi, S Poty… - Pharmaceutics, 2021 - mdpi.com
Auger electron emitters (AEEs) are attractive tools in targeted radionuclide therapy to
specifically irradiate tumour cells while sparing healthy tissues. However, because of their short …

Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines

N Curado, G Dewaele-Le Roi, S Poty… - Chemical …, 2019 - pubs.rsc.org
We describe the preparation of gold(I)-compounds that are amenable to efficient bioconjugation
with monoclonal antibodies via activated ester or maleimide linkers. New Trastuzumab–…

Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer

JF Bai, SR Majjigapu, B Sordat, S Poty, P Vogel… - European Journal of …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which
chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-…